X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Sunosi (solriamfetol) is a dopamine and norepinephrine reuptake inhibitor and trace amine-associated receptor 1 (TAAR1) agonist. It is being evaluated for the treatment of binge eating disorder.
Lead Product(s): Solriamfetol Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Sunosi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
AXS-12 (reboxetine) is a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator. It is being evaluated for the treatment of Narcolepsy.
Lead Product(s): Reboxetine Mesylate
Therapeutic Area: Sleep Product Name: AXS-12
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2024
Details:
Sunosi (solriamfetol) is a dopamine and norepinephrine reuptake inhibitor and trace amine-associated receptor 1 (TAAR1) agonist. It is being evaluated for the treatment of major depressive disorder.
Lead Product(s): Solriamfetol Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Sunosi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
Details:
Sunosi (solriamfetol), is a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with Attention Deficit Hyperactivity Disorder (ADHD) in Adults.
Lead Product(s): Solriamfetol Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Sunosi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2023
Details:
Axsome intends to use the proceeds to advance its late-stage pipeline, including AXS-05 (dextromethorphan-bupropion), a novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed for the treatment of central nervous system conditions.
Lead Product(s): Dextromethorphan,Bupropion Hydrochloride
Therapeutic Area: Neurology Product Name: AXS-05
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SVB Securities
Deal Size: $225.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 30, 2023
Details:
Axsome intends to use the proceeds to advance its late-stage pipeline, including AXS-05 (dextromethorphan-bupropion), a novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed for the treatment of central nervous system conditions.
Lead Product(s): Dextromethorphan,Bupropion Hydrochloride
Therapeutic Area: Neurology Product Name: AXS-05
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SVB Securities
Deal Size: $225.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 28, 2023
Details:
Axsome intends to use the proceeds to advance its late-stage pipeline, including AXS-05 (dextromethorphan), a novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed for the treatment of central nervous system conditions.
Lead Product(s): Dextromethorphan,Bupropion Hydrochloride
Therapeutic Area: Neurology Product Name: AXS-05
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SVB Securities
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering June 27, 2023
Details:
Under the agreement, Pharmanovia will be responsible for the development and marketing of Sunosi (solriamfetol), a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults with EDS due to narcolepsy or OSA, in Europe and MENA regions.
Lead Product(s): Solriamfetol Hydrochloride
Therapeutic Area: Sleep Product Name: Sunosi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pharmanovia
Deal Size: $167.0 million Upfront Cash: $66.0 million
Deal Type: Licensing Agreement February 22, 2023
Details:
AUVELITY is a novel, oral, NMDA receptor antagonist with multimodal activity approved for the treatment of MDD in adults. AUVELITY is a proprietary extended-release oral tablet containing dextromethorphan HBr (45 mg) and bupropion HCl (105 mg).
Lead Product(s): Dextromethorphan Hydrobromide,Bupropion Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Auvelity
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
AXS-05 (dextromethorphan-bupropion) is novel, oral, patent protected, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer’s disease (AD) agitation and other CNS disorders.
Lead Product(s): Dextromethorphan,Bupropion Hydrochloride
Therapeutic Area: Neurology Product Name: AXS-05
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
